Your session is about to expire
← Back to Search
Other
Hypofractionated IMRT for Head and Neck Cancer
Phase 1 & 2
Recruiting
Led By Dominic Moon, MD
Research Sponsored by University of Texas Southwestern Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
ECOG performance status 0-2
Age ≥18 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12-24 months
Awards & highlights
Study Summary
This trial is testing a new way to give radiation therapy that may be better than the current standard.
Who is the study for?
This trial is for adults with stage I-IVB squamous cell carcinoma of the oral cavity or related areas, who've had surgery but still have intermediate risk factors. They must be in fair health, able to consent, and use birth control if needed. Excluded are those with distant cancer spread, prior radiation in the area, severe illnesses that affect study compliance, pregnant/nursing women, high-risk surgical outcomes needing chemo, certain immune conditions or other cancers.Check my eligibility
What is being tested?
The HYPORT trial tests a shorter course of post-op radiation therapy (IMRT) for head and neck cancer patients. Phase 1 checks safety and tolerability to find the right dose; Phase 2 compares swallowing quality of life and effectiveness against standard longer-term radiation treatments.See study design
What are the potential side effects?
Potential side effects include skin reactions at the treatment site, dry mouth or throat changes affecting swallowing ability due to inflammation from IMRT. There may also be fatigue and possible acute toxicity as assessed in Phase 1.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I can take care of myself and am up and about more than half of the day.
Select...
I am 18 years old or older.
Select...
I had surgery to remove cancer from my mouth or throat and it was somewhat risky.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12-24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12-24 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Phase 1: Maximally tolerated dose of hypofractionated radiation therapy
Phase 2: Swallowing-related patient-reported quality of life
Secondary outcome measures
Clinician-reported acute toxicities
Clinician-reported late toxicities
Feeding tube dependence
+6 moreTrial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Hypofractionated radiotherapyExperimental Treatment1 Intervention
Dose and fractionation determined by Phase I:
Level 1: 44.4 Gy in 12 fractions, 4 fractions/week
Level 0: 46.5 Gy in 15 fractions, 5 fractions/week
Level -1: 52 Gy in 20 fractions, 5 fractions/week
Level -2: 50 Gy in 20 fractions, 5 fractions/week
Group II: Conventionally fractionated radiotherapyActive Control1 Intervention
60 Gy in 30 fractions, 5 fractions/week
Find a Location
Who is running the clinical trial?
University of Texas Southwestern Medical CenterLead Sponsor
1,048 Previous Clinical Trials
1,053,713 Total Patients Enrolled
Dominic Moon, MDPrincipal Investigator - UT Southwestern Medical Center
University of Texas Southwestern Medical Center
1 Previous Clinical Trials
24 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I can take care of myself and am up and about more than half of the day.My cancer is a stage I or II squamous cell carcinoma of the glottis.My cancer has spread to distant parts of my body.I am 18 years old or older.I need chemotherapy along with surgery due to high risk factors.I have a history of severe immune system problems, including HIV, or have had an organ or stem cell transplant.I had cancer before and it's likely to return within 3 years.I have had radiation therapy on the cancer area being studied.I agree to use birth control during the study.I am not dependent on a feeding tube in Phase II.I have another type of cancer that is not skin cancer or in the specified areas.I do not have any unmanaged ongoing illnesses.I had surgery to remove cancer from my mouth or throat and it was somewhat risky.
Research Study Groups:
This trial has the following groups:- Group 1: Conventionally fractionated radiotherapy
- Group 2: Hypofractionated radiotherapy
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
To what extent is patient participation in this research endeavor?
"Affirmative. Clinicaltrials.gov data confirms that this medical experiment, which was first posted on July 28th 2020, is currently seeking participants. Around 98 subjects need to be enlisted from 1 specified clinic."
Answered by AI
Are there opportunities to participate in this investigation?
"Affirmative. According to information published on clinicaltrials.gov, the trial first announced on July 28th 2020 is still looking for 98 participants at a single site and was recently updated on October 7th 2022."
Answered by AI
Share this study with friends
Copy Link
Messenger